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Background: The connection between gut microbiota and metabolism and its role in
the pathogenesis of diabetes are increasingly recognized. The objective of this study
was to quantitatively measure Bifidobacterium and Lactobacillus species, members of
commensal bacteria found in human gut, in type 2 diabetic patients (T2D) patients from
Southern China.
Methods: Fifty patients with T2D and thirty control individuals of similar body mass index
(BMI) were recruited from Southern China. T2D and control subjects were confirmed with
both oral glucose tolerance test (OGTT) and HbA1c measurements. Bifidobacterium and
Lactobacillus species in feces were measured by real-time quantitative PCR. Data were
analyzed with STATA 11.0 statistical software.
Results: In comparison to control subjects T2D patients had significantly more total
Lactobacillus (+18%), L. bugaricus (+13%), L. rhamnosum (+37%) and L. acidophilus
(+48%) (P < 0.05). In contrast, T2D patients had less amounts of total Bifidobacteria
(−7%) and B. adolescentis (−12%) (P < 0.05). Cluster analysis showed that gut microbiota
pattern of T2D patients is characterized by greater numbers of L. rhamnosus and
L. acidophillus, together with lesser numbers of B. adolescentis (P < 0.05).
Conclusion: The gut microflora in T2D patients is characterized by greater numbers of
Lactobacillus and lesser numbers of Bifidobacterium species.
Keywords: microbiota, microflora, metabolic diseases, gut
INTRODUCTION
The pathophysiology of type 2 diabetes (T2D) involves both envi-
ronmental and genetic factors. Recently, the gut microflora has
emerged as another parameter at the crossroad of these interac-
tions. Several animal and human studies have demonstrated that
the gutmicroflora composition differs between T2D and controls,
and may play a role in the development of insulin resistance and
T2Ds (Cani et al., 2008; Delzenne and Cani, 2011). In addition, it
has been shown that modification of the gut microbiota by envi-
ronmental factors may alter body weight and energy metabolism
regulation, which may lead to the development of obesity, the
major risk factor for T2D (Backhed et al., 2004; Tremaroli et al.,
2010).
More than 1012 microorganisms can be found in the human
colon (Eckburg et al., 2005; Andersson et al., 2008). Of these, the
Firmicutes, Bacteroides, Actinobacteria, and Proteobacteria phyla
are the most prominent (Arumugam et al., 2011). These bacteria
can be categorized as commensal, beneficial, or harmful. Some
of the deleterious effects include activation of inflammatory
processes, alteration of the intestinal barrier, and modification
of metabolic pathways (Cani et al., 2008); while beneficial effects
include anti-inflammatory effects, improved nutrient digestion,
and absorption and regulation of lipid metabolism (Russell et al.,
2011). Until now, most studies investigating the gut micro-
biota composition have used large throughput screening methods
to distinguish specific patterns between various patient types
(Larsen et al., 2010). One report indicates that Bifidobacterium
is underrepresented in T2D patients compared to controls, and
may possibly play a role in the development of T2D (Wu et al.,
2010b).
Bifidobacterium and Lactobacillus belong to the Actinobacteria
and Firmicutes phyla, respectively. In addition to the fact that these
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genera are highly prevalent in the human gut, they also are added
as probiotics in foods, making them therefore ideal candidates
for potential clinical interventions. Effects of the various strains
of bacteria on health can be very divergent, and it still remains
unclear which species are responsible for specific metabolic
effects. In mice, administration of Lactobacillus casei improves
diet-induced obesity and insulin resistance (Naito et al., 2011).
However, it has also been shown that presence of certain
Lactobacillus species may increase inflammation, which may be
related to obesity and T2D (Zeuthen et al., 2006; Santacruz et al.,
2009). Increasing the content of gut Bifidobacterium resulting
from a prebiotic dietary fiber intervention improved high-fat
diet-induced glucose intolerance, insulin secretion, and low-
grade inflammation (Cani et al., 2007). Until now, most studies
have been performed in Caucasian populations leaving unknown
whether the gut microflora may have similar relationships to
metabolism in other ethnicities.
Therefore, the primary aim of this study was to determine if
there are specific species differences in total Lactobacillus, L. aci-
dophilus, L. bulgaricus, L. casei, L. rhamnosus, L. plantarum, Total
Bifidobacterium, B. longum, B. breve, B. adolescentis, and B. infan-
tis between T2D and control patients in Southern China.
MATERIALS AND METHODS
STUDY SUBJECTS
Diabetic subjects and control subjects were selected for this
prospective study based on inclusion criteria listed below between
March 2008 and January 2010 at Southern Medical University in
Guangzhou, Southern China. Subjects with normal oral glucose
tolerance test (OGTT) and HbA1C measurements (see below)
were selected as controls. Fifty T2D patients and thirty control
subjects of broad age (20–76 years) and body mass index (BMI)
(17–36 kg/m2) ranges were included in this study. Patients were
defined as T2D if their fasting and 2-h OGTT glucose values
were ≥7.0mmol/l and ≥11.1mmol/l respectively, and if they had
disease duration of at least 5 years duration but otherwise healthy,
age 18–80 years, male or female, stable glycemic control (mean
HbA1c levels<8.0%).
All T2D patients had made lifestyle modifications and
21/50 patients took medications, such as metformin, acar-
bose, glyburide or Chinese herbal medicine (Pueraria skull-
cap Coptis soup), and achieved glycemic control (HbA1c of
6–7%, Preprandial blood glucose: 4.0–6.0mmol/L, 2-h postpran-
dial blood glucose: 5.0–8.0mmol/L.), While the control sub-
jects with normal OGTT had A1C of 4.2–6.3% (mean, 5.4%).
All patients and control subjects were selected from Southern
Medical University hospitals; and most of them lived in the same
community and ate a southern Chinese style diet twice a day.
Participants were excluded if there was any evidence of
diarrhea, constipation, significant cardiovascular complications,
microalbuminuria (>40mg per 24 h) or frank proteinuria, evi-
dence of unstable glycemic control (mean HbA1c levels > 8.0%),
or history of admission for hyperglycemia or hypoglycemia in the
6 months prior to recruitment, other significant renal, hepatic,
cardiovascular, or neurological disease; cancer; pregnancy. All
participants provided their signed written consent and this study
protocol was approved by the Ethical Committee of Southern
Medical University.
ANTHROPOMETRY AND METABOLIC QUANTIFICATIONS
Weight and height weremeasured to the nearest 0.1 kg and 0.1 cm,
respectively, using a beam medical scale and wall-mounted
stadiometer; and BMI was calculated as previously described
(Zeuthen et al., 2006). All patients stopped taking their diabetes
medications for 3 days and had overnight fast before investigation
Glucose tolerance was evaluated using 75 g oral dose of glucose.
Venous blood samples were drawn twice from antecubital vein.
The first sample was drawn at 8–10AM after overnight fasting
for at least 12 h, and the second samples was drawn 2 h after
75 g oral glucose loading. The first blood sample was examined
for baseline metabolic profiles [hemoglobin (HbA1c, C-peptide,
C-reactive protein, fasting blood glucose, cholesterol, triglyc-
eride, high-density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C))]. The second blood sample was
examined for blood glucose and insulin levels. Fecal specimens
were collected within 12 h after the administration of oral glucose
for subsequent measurement of bacterial composition.
Blood analysis
Blood samples were centrifuged immediately for 10min at
2500 RPM at 8–10◦C. Then the serum was removed and frozen
at −70◦C until assayed. Glucose was assayed in duplicate on
a Yellow Springs Instrument 2700 Analyzer (Yellow Springs
Instrument, Yellow Springs, OH) using the glucose oxidase
method, and Glycated hemoglobin (HbA1c) was measured
by using a HPLC cation exchange column method (Modular
Diabetic Monitoring System; Bio-Rad, Richmond, CA).
C-peptide was determined by ELISA (DRG-Diagnostica,
Marburg, Germany).
Extraction of bacterial DNA from fecal samples
Total bacterial DNA was extracted from the fecal samples
using DNA stool kit according to the manufacture’s protocol
(Qiagen, Valencia, CA, USA). DNA concentration and quality
in the extracts was determined by agarose gel electrophoresis.
Altogether, nine species of probiotic bacteria were chosen for
measurement including L. acidophilus, L. bulgaricus, L. casei,
L. rhamnosus, B. breve, B. longum, and B. infantis. Specific forward
and reverse primers for each bacterium were designed (Table 1).
Real-time qPCR
Bacterial copy numbers in fecal samples from 50 subjects with
T2D and 30 controls were quantified by qPCR using the 7500 Fast
Real-time PCR system (Applied Biosystems, USA). The qPCR
reaction mixture (20μl) was composed of each 0.6μl forward
and reverse primer, 6.4μl sterile ddH2O, ROX Reference Dye
(50 X) 0.4μl, SYBR premix DimerEraser (2 X) 10μl (Takara,
Biotechnology, Dalian, China) and 2μl fecal DNA as template
added in 10-fold serial dilutions from 102 to 1012 copy/ml. The
amplification program consisted of one cycle of 95◦C for 30s, fol-
lowed by 40 cycles of 95◦C for 5 s, 55◦C for 30 s, and 72◦C for
34 s. Each fecal sample measurement was performed in duplicate.
Standard curves were constructed using 10-fold serial dilutions
of fecal bacterial DNA of known concentration. Copy numbers
of bacteria in fecal samples were calculated from the threshold
cycle values (Ct) and expressed as quantity of bacteria per gram
feces. Since data were not normally distributed, these values were
subsequently transformed using logarithm.
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Table 1 | PCR primers for detection of Bifidobacterium and Lactobacillus.
Gut flora Forward primer 5′–3′ Reverse primer 5′–3′ Size (bp) References
Lactobacillus AGCAGTAGGGAATCTTCCA CACCGCTACACATGGAG 341 Armougom et al., 2009
Lactobacillus acidophilus GAAAGAGCCCAAACCAAGTGATT CTTCCCAGATAATTCAACTATCGCTTA 145 Wellen and Hotamisligil, 2005
Lactobacillus bulgaricus GGRTGATTTGTTGGACGCTAG GCCGCCTTTCAAACTTGAATC 138 Wu et al., 2010a
Lactobacillus casei GCACCGAGATTCAACATGG GGTTCTTGGATYTATGCGGTATTAG 122 Wu et al., 2010a
Lactobacillus rhamnosus TGCTTGCATCTTGATTTAATTTTG GTCCATTGTGGAAGATTCCC 317 Wu et al., 2010a
Lactobacillus plantarum TGGATCACCTCCTTTCTAAGGAAT TGTTCTCGGTTTCATTATGAAAAAATA 145 Haarman and Knol, 2006
Bifidobacterium GCGTGCTTAACACATGCAAGTC CACCCGTTTCCAGGAGCTATT 126 Armougom et al., 2009
Bifidobacterium longum GAGACAGAAACTTTCGAAGC GAAGTCTGTGGTATCCAATCC 112 Byun et al., 2004
Bifidobacterium breve TTCCGCATTCGTGTTATTGA CACATCTTCGCTATCCAGCA 279 Byun et al., 2004
Bifidobacterium adolescentis CTCCAGTTGGATGCATGTC CGAAGGCTTGCTCCCAGT 122 Matsuki et al., 1998
Bifidobacterium infantis CCATCTCTGGGATCGTCGG TATCGGGGAGCAAGCGTGA 563 Matsuki et al., 1998
STATISTICAL METHODS
All data aremeans± SD. Statistical analyses were performed using
STATA 11.0 (Stata Corp, College Station, TX). P-values <0.05
was considered statistically significant. Values for bacterial con-
tent were transformed using logarithm in order to reach a normal
distribution. Unadjusted paired comparisons were done using
Student t-tests. Adjustments of comparisons for age and gen-
der were performed using analysis of covariance (ANCOVA).
Bacterial content patterns were evaluated using cluster analy-
sis of observations, which separates participants into mutually
exclusive groups and maximizes differences in the content of a
number of bacteria. The cluster k-means procedure in STATA,
version 11.0, was used, based on the K-means method. The rela-
tionship between the two clusters identified and the presence of
diabetes was tested using the chi-squared test. Differences among
clusters were investigated using the Kruskal–Wallis analysis of
variance test.
RESULTS
A total of 30 control participants (43% females) and 50 patients
with T2D (54% females) completed the study. Anthropometric
characteristics of the two groups are presented in Table 2. T2D
patients were significantly older than the control group (60 ± 8
vs. 41 ± 11 years, P < 0.001), and subsequent analyses were thus
adjusted for age. T2D patients had significantly greater amount of
the total Lactobacillus, as well as greater amounts of L. bulgaricus,
L. casei, L. rhamnosus and L. acidophillus, compared to controls
(Table 3). However, when adjusted for age and gender, the dif-
ferences for L. casei were no longer significant. T2D patients had
less numbers of total Bifidobacterium and B. adolescentis than con-
trols. These differences remained significant when adjusted for
age and gender.
Cluster analysis identified twomutually exclusive clusters char-
acterized as follows: cluster 1 had greater numbers of L. rham-
nosus and L. acidophillus, and a lesser numbers of B. adolescentis
(Figure 1 and Table 4). Cluster 2 had the opposite description,
i.e., lesser numbers of L. rhamnosus and L. acidophillus, and
a greater numbers of B. adolescentis. Interestingly, there was a
strong association between the clusters and the presence of dia-
betes (p-value of chi-squared test: P < 0.001), suggesting that
the presence of diabetes may be characterized by a specific
Table 2 | Anthropometric parameters.
Parameter Control (n = 30) Diabetic (n = 50) P-value
Sex (M/F) 17/13 23/27 0.3
Age (years) 41 ± 11 60 ± 8 <0.001
Weight (kg) 64.2 ± 9.0 62.9 ± 10.0 0.7
BMI (kg/m2) 23.9 ± 3.0 24.7 ± 3.8 0.5
gut microflora pattern. Thus, greater numbers of L. rhamnosus
and L. acidophillus, and a lesser numbers of B. adolescentis, are
high specificity descriptors of Cluster 1 for T2D. Sensitivity and
specificity calculations of this cluster analysis showed that for such
bacterial analysis and prediction of T2D, the sensitivity = 0.62,
specificity = 0.97, positive predictive value = 0.97 and negative
predictive value = 0.60.
Patients took multiple medications including metformin, the
prescriptions were personalized so that there were different doses
of medications in variety combinations.We comparedmetformin
group with other patients group, no difference has been observed.
DISCUSSION
Previous studies have shown that specific gut microbiota compo-
sition is linked to the presence of T2D (Larsen et al., 2010; Wu
et al., 2010b). In the present study, we showed that in a Southern
Chinese population, T2D patients have increased numbers of
L. Bulgaricum, L. rhamnosus and L. acidophillus and decreased
numbers of B. Adolescentis, compared to controls. Together, this
set of bacteria formed a cluster characteristic of T2D patients.
Previous studies have shown that T2D patients had greater
numbers of Lactobacillus and lesser numbers of Bifidobacterium
in their gut as measured in feces compared to non-diabetic
patients. Our results obtained in Chinese subjects are in line
with these studies. In addition, we further measured individual
species of Lactobacillus and Bifidobaterium and showed that
several Lactobacillus species, namely L. bulgaricum, L. rhamnosus
and L. acidophillus are increased in number in T2D patients.
The role of Lactobacillus in metabolic diseases remains unclear.
Administration of L. casei strain improved glucose tolerance in
diet-induced obese mice (Naito et al., 2011). In contrast, other
studies point to a pro-inflammatory role of Lactobacillus.
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Table 3 | Comparisons of bacteria amounts between controls and diabetic patients (bacterial values transformed using logarithm).
Control (n = 30) Diabetic (n = 50) Unadjusted P-value P-value adjusted for age and gender
Lactobacillus
Lactobacillus bulgaricus 4.6 ± 0.8 5.2 ± 0.6 0.0006 0.03
Lactobacillus casei 4.5 ± 0.9 5.0 ± 1.0 0.03 0.19
Lactobacillus plantarum 4.6 ± 0.7 4.7 ± 0.9 0.9 0.68
Lactobacillus rhamnosus 2.7 ± 0.4 3.7 ± 1.0 <0.0001 0.004
Lactobacillus acidophillus 2.9 ± 0.6 4.3 ± 1.4 <0.0001 0.01
Lactobacillus (total) 6.6 ± 0.5 7.8 ± 0.9 <0.0001 0.0005
Bifidobacterium
Bifidobacterium longum 3.9 ± 0.8 3.7 ± 0.7 0.15 0.2
Bifidobacterium breve 3.9 ± 0.3 3.9 ± 0.3 0.4 0.4
Bifidobacterium adolescentis 4.0 ± 0.3 3.5 ± 0.4 <0.0001 0.0003
Bifidobacterium infantis 3.9 ± 1.0 4.0 ± 0.9 0.7 0.3
Bifidobacterium (total) 11.6 ± 0.9 10.7 ± 0.7 <0.0001 0.002
FIGURE 1 | Schematic representation of the two clusters (bacterial values transformed using logarithm).
For example, obese individuals have greater numbers
of Lactobacillus in their feces, compared to lean controls
(Armougom et al., 2009). Obesity is characterized by a chronic,
low-grade inflammation, which may lead to the development
of insulin resistance and ectopic fat deposition (Wellen and
Hotamisligil, 2005). Although the mechanisms remain unknown,
it has been speculated that modifications of the gut microbiota
may increase local and plasma lipopolysaccharide (LPS), which
may in turn lead to inflammation, hepatic fat accumulation,
insulin resistance, and T2D (Cani et al., 2008). In our study,
Lactobacillus levels were not related to plasma C-reactive proteins
concentrations, a measure of inflammation (data not shown).
However, presence of such bacteria may locally induce inflamma-
tion or other cytokines that we did not measure, such as TNF-α
or IL-6.
We also showed that Bifidobacterium numbers were decreased
in T2D patients. Our results support previous studies, showing
that both insulin resistant and obese patients have decreased
Bifidobacterium numbers in their gut (Larsen et al., 2010; Wu
et al., 2010b). In the present study, the only species that was sig-
nificantly different was B. adolescentis. B. adolescentis has been
shown to reduce intestinal permeability, thus providing a bet-
ter protection against endotoxin translocation (Wu et al., 2010a).
Previous studies suggest that high-fat diet-induced endotox-
emia could modify gut microbiota, and lead to a decrease in
Bifidobacterium species (Cani et al., 2007). The pathogenesis of
T2D is strongly influenced by environmental factors, such as
diet. Therefore, it remains possible that poor nutritional habits
may in the long term contribute to modification of the gut
microbiota, which may in turn play a role in the development
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Table 4 | Comparisons of bacteria amount by clusters (bacterial values transformed using logarithm).
Cluster 1 (n = 32) Cluster 2 (n = 48) Unadjusted P-value P-value adjusted for age and gender
Cases of Diabetes (%) 31 (97%) 19 (40) <0.0001
Lactobacillus
Lactobacillus bulgaricus 5.1 ± 0.6 4.9 ± 0.8 0.09 0.01
Lactobacillus casei 5.2 ± 1.2 4.5 ± 0.8 0.003 0.2
Lactobacillus plantarum 4.8 ± 0.9 4.6 ± 0.8 0.21 0.6
Lactobacillus rhamnosus 4.0 ± 1.0 2.9 ± 0.5 <0.0001 0.0001
Lactobacillus acidophillus 5.1 ± 0.9 2.8 ± 0.5 <0.0001 <0.0001
Lactobacillus (total) 7.7 ± 0.9 7.0 ± 0.9 0.001 0.02
Bifidobacterium
Bifidobacterium longum 3.5 ± 0.7 3.9 ± 0.8 0.06 0.6
Bifidobacterium breve 3.9 ± 0.3 3.9 ± 0.3 0.4 0.2
Bifidobacterium adolescentis 3.4 ± 0.2 3.9 ± 0.4 <0.0001 0.003
Bifidobacterium infantis 3.9 ± 0.8 4.0 ± 1.0 0.5 0.7
Bifidobacterium (total) 10.7 ± 0.7 11.2 ± 0.9 0.03 0.4
of T2D. Further mechanistic studies will be required to assess
causal relationships.
Based on these various differences in gut microbiota com-
position between T2D patients and the control individuals, we
further aimed to assess whether T2D could be characterized by
a specific “bacterial signature.” Using cluster analysis, we identi-
fied two mutually exclusive clusters. Cluster 1 was characterized
by high amount of L. Rhamnosus and L. acidophillus, while lower
amount of B. adolescentis. Interestingly, all except one individual
in Cluster 1 had T2D, suggesting that such analysis can provide
high specificity for the disease. Indeed, the specificity for such
test was 0.97, and the positive predictive value reached the same
score of 0.97. This suggests that most individuals identified with
Cluster 1 have a high probability of being diabetic. However, the
number of cases of “false negative” remained high, with a sen-
sitivity of 0.62 and a negative predictive value of 0.60. Of note,
it is not clear why one individual in Cluster 1 did not have dia-
betes. However, considering the very high sensitivity of Cluster
in patients with diabetes, it is conceivable that this one patient
represents the metabolic phenotype of diabetes without the usual
clinical measures of diabetes. On the other hand, the high false
negative rate of Cluster 1 designation for diabetes patients sug-
gests that Cluster 1 designation represents a unique metabolic
subset of patients with diabetes. These suggestions may lead to
further investigations to understand the mechanisms of these dif-
ferences in the patient groups. Therefore, more accurate evalua-
tion and refined analysis of gut bacteria will need to be performed.
In addition, the relationship between the changes of the gut
microbiota and the development of T2Ds should be investigated
in a prospective cohort study, which would be useful to iden-
tify individuals at high risk for T2D. Although these preliminary
results need to be further validated by larger number of patients
and more refined bacterial analysis, they may provide some
direction for development of future diagnostic tool to identify
individuals at high risk for T2D and initiate early prevention and
treatment.
The potential clinical impacts of this study are 2-fold: first, we
have identified a bacterial signature of T2D, which may be further
developed and possibly used as a future diagnostic tool for iden-
tification of patients at risk for T2D. Second, our findings may
lead to dietary recommendations for gut microbiota modulation
such as diets promoting increased Bifidobacterium. In conclusion,
we showed that T2D patients can be characterized by a specific
fecal bacterial pattern of Lactobacillus and Bifidobacterium species.
Modification of these bacteria levels, may influence T2D.
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